Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

Update: 2025-03-28

Description

Today’s guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.

Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.

It has become an iconic name in the field of artificial intelligence for drug discovery.

TPM E44 highlights >⁠⁠⁠⁠⁠⁠⁠

Episode 44 links:

Comments

In Channel

Mida Pezeshkian, Stema_cg | Launching products in healthcare: The most important framework is flexibility | TPM podcast #49

2025-08-2944:30

Michael Montalto, Amgen | How to have the biggest impact on patients: a career of invention, innovation, and implementation | TPM podcast #48

2025-07-2443:24

Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47

2025-06-2442:43

Stéphane Budel, DeciBio | Precision medicine is our future and our fate | TPM podcast #46

2025-05-1950:02

Anna Berkenblit & Sudheer Doss, PanCAN | On a mission to beat an ignoble killer: pancreatic cancer | TPM podcast #45

2025-04-2246:10

Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

2025-03-2838:35

Ryan Fukushima | Reinventing diagnostics: The superpower of not knowing what can’t be done | TPM #43

2025-02-2643:19

The journey to the top of life sciences technology: a lifetime of listening and learning | Talking Precision Medicine #42

2025-01-3147:34

The view from 30,000: Healthcare & life science AI in the cloud | Talking Precision Medicine #41

2024-12-1837:10

What’s in a digital twin? Inventing new kinds of AI for biomedicine | Talking Precision Medicine #40

2024-11-1547:02

Leave No Patient Behind—R&D Tools and Cutting Edge Diagnostics that Span the Globe | Talking Precision Medicine #39

2024-10-0835:38

Zola-007: Giving T-cells the license to kill | Talking Precision Medicine #38

2024-08-2944:06

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

2024-07-2239:01

Tackling healthcare disparities and bridging the digital divide: it doesn’t have to be so hard | Talking Precision Medicine #36

2024-05-2444:13

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

2024-04-1231:27

Professional grade software — a key ingredient in cutting edge biomedical discovery | Talking Precision Medicine #34

2023-12-1431:38

New Medicines from Evolutionary Pathways: Using Comparative Genomics to Treat Human Disease | Talking Precision Medicine #33

2023-10-2742:45

To achieve personalized medicine, start by getting the dose right | Talking Precision Medicine #32

2023-08-0239:13

AI and Ethics in Healthtech: Who is Innovating Most? | Talking Precision Medicine #31

2023-06-2934:41

People first: building a company that inspires impactful work | Talking Precision Medicine #30

2023-05-3151:06

00:00

1.0x

Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

#box-pro-ellipsis-175883088753277{-webkit-line-clamp:2;}Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

Genialis

Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44